Page last updated: 2024-12-08

triacetoneamine-n-oxyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triacetoneamine-N-Oxyl: Cyclic N-oxide radical functioning as a spin label and radiation-sensitizing agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-oxo-TEMPO : A member of the class of aminoxyls that is TEMPO carrying an oxo group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID520789
CHEMBL ID606972
CHEBI ID180665
MeSH IDM0021889

Synonyms (36)

Synonym
4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl
2,2,6,6-tetramethyl-4-oxopiperidine-1-oxyl
CHEBI:180665
4-oxo-2,2,6,6-tetramethylpiperidinyloxyl
1-piperidinyloxy, 2,2,6,6-tetramethyl-4-oxo-
piperidinooxy, 2,2,6,6-tetramethyl-4-oxo-
ai3-61971
einecs 220-778-7
tempone
brn 1818579
triacetoneamine-n-oxyl
2,2,6,6-tetramethyl-4-oxopiperidinooxy
2,2,6,6-tetramethyl-4-oxo-piperidin-1-oxyl
4-oxo-tempo
4-oxo-2,2,6,6-tetramethylpiperidine 1-oxyl, free radical
4-oxo-2,2,6,6-tetramethylpiperidine 1-oxyl
O0266
CHEMBL606972
AKOS007930674
unii-7w1863peh5
7w1863peh5 ,
ec 220-778-7
dtxcid2024905
dtxsid4044905 ,
cas-2896-70-0
tox21_301269
NCGC00256228-01
1-$l^{1}-oxidanyl-2,2,6,6-tetramethyl-piperidin-4-one
1-$l^{1}-oxidanyl-2,2,6,6-tetramethyl-4-piperidinone
A819695
80404-14-4
4-oxo-2,2,6,6-tetramethyl-1-piperidinyloxy, free radical
4-oxo-tempo-d16,1-15n, free radical
2,2,6,6-tetramethyl-4-piperidone 1-nitroxide
AS-12251
4-oxo-tempo free radical

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Nitroxides (10 mM) were added 10 min prior to radiation exposure and full radiation dose-response curves were determined."( Identification of nitroxide radioprotectors.
DeGraff, W; Gamson, J; Hahn, SM; Krishna, CM; Liebmann, J; Mitchell, JB; Samuni, A; Venzon, D; Wilson, L, 1992
)
0.28
"TBI induced injury is highly dependent on the irradiation dosage in small intestine and inversely correlates with the energy metabolism, with its reduction potentially indicating the severity of injury."( Irradiation induced injury reduces energy metabolism in small intestine of Tibet minipigs.
Chen, C; Gu, WW; Guo, KY; Liu, W; Song, J; Wang, G; Wang, YJ; Wu, QH; Yan, LM, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
piperidones
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.61130.001628.015177.1139AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.966219.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID216900Mean surviving fraction of V79 cells following a 12-Gy dose of radiation.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID572090Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID216890Mean surviving fraction of V79 cells following a 1-h exposure to H2O2.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID572091Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (32.06)18.7374
1990's34 (25.95)18.2507
2000's30 (22.90)29.6817
2010's24 (18.32)24.3611
2020's1 (0.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.41 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.73%)0.25%
Other135 (98.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]